Oncology News

Oncology

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Tsai-Turton M et al. - Type II, but not type I, ovarian carcinoma patients had elevated serum levels of p53 AAb. P53 AAb is associated with mutation of TP53, higher plasma IL4 and IL12 but lower plasma IL8 levels and no survival advantage.

Related Articles

Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer
BMC Cancer, 11/04/09    Relevance Score: 66%

Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis
Cancer Chemotherapy and Pharmacology, 10/15/09    Relevance Score: 47%

Preventing future cancers by testing women with ovarian cancer for brca mutations
Journal of Clinical Oncology, 10/22/09    Relevance Score: 46%

Oxidative stress status in normal ovarian cortex surrounding ovarian endometriosis
Fertility and Sterility, 10/14/09    Relevance Score: 46%

Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
BMC Cancer, 10/21/09    Relevance Score: 45%

Today in Carcinogenesis...keeping you current

Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways
Endocrine-Related Cancer, 12/08/09

Activation of the hedgehog-signaling pathway in human cancer and the clinical implications
Oncogene, 11/30/09

Association of rare MSH6 variants with familial breast cancer
Breast Cancer Research and Treatment, 11/25/09

Today in Gynecologic Oncology...keeping you current

Recreational physical activity and risk of epithelial ovarian cancer
Cancer Causes and Control, 12/14/09

The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer
Clinical and Translational Oncology, 12/14/09

Gonadotropin and steroid receptors as prognostic factors in advanced ovarian cancer: a retrospective study
Clinical and Translational Oncology, 12/14/09